Search results
Results from the WOW.Com Content Network
Henry A. McKinnell, Jr. (born February 23, 1943) is an American business executive, who served as the chief executive officer and chairman of the board of directors of Pfizer Inc. from 2001 to 2006/2007. He is also a director of Moody's.
During his tenure at Pfizer, the company grew from $500 million in worldwide sales to $50 billion. At Pfizer he was president of the Pfizer Foundation and worked closely with then CEO Hank McKinnell on providing healthcare assistance to HIV AIDs patients in the US and Africa, especially in Uganda. He spent three months in Vietnam working on the ...
Following this, with Pfizer’s acquisition of Warner Lambert, Katen managed the largest integration in the history of the U.S. pharmaceutical industry. [2] During the early 2000s, Katen was one of three Vice-Chairmen widely speculated to vie for the CEO position when then-CEO Henry "Hank" McKinnell Jr. was set to retire. [4]
Pfizer CEO Albert Bourla is breathing a little easier after strong third quarter earnings results Tuesday and after the company raised full-year guidance by $1.5 billion, bringing an end to a ...
Pfizer CEO is no stranger to risks, and hopes to repeat the company's COVID-19 success with an oral treatment. Pfizer authorizes $1 billion for oral COVID-19 treatment, CEO says [Video] Skip to ...
COVID-19 gave a shot in the arm to Pfizer's sales and culture. Now CEO Albert Bourla lays out a plan to replace vaccine revenue as the virus' impact wanes.
On July 28, 2006, Pfizer's board of directors selected Kindler to succeed Henry A. McKinnell Jr. as chief executive officer. Later in 2006, Kindler was elected by Pfizer's board of directors to serve the additional role of chairman. [10] In 2009, Kindler oversaw Pfizer's $68 billion acquisition of Wyeth. [11]
Yahoo Finance's Anjalee Khemlani spoke with Pfizer CEO Albert Bourla about how the company increased production of COVID-19 vaccines to meet high demand.